Novo Nordisk: indication extension approved for Fiasp
(CercleFinance.com) - The European Commission has approved the use of Fiasp, the fast-acting insulin developed by Novo Nordisk, for children and teenagers, the Danish group said on Thursday.
The pre-filled pen injection solution of the world's leader in diabetes treatments was previously only indicated for adults.
According to the Fiasp dosing regimen, the drug can be taken up to two minutes before a meal and up to 20 minutes after the start of a meal.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The pre-filled pen injection solution of the world's leader in diabetes treatments was previously only indicated for adults.
According to the Fiasp dosing regimen, the drug can be taken up to two minutes before a meal and up to 20 minutes after the start of a meal.
Copyright (c) 2019 CercleFinance.com. All rights reserved.